Rationale: Despite effective treatments, a large proportion of asthma patients do not achieve sustained asthma control. The 'preventable' burden associated with lack of proper control is likely taking a high toll at the population level.
Introduction
Asthma is a very common chronic disease globally. The prevalence of asthma has increased over the last decade in many regions of the world(1). Despite the fact that asthma imposes a substantial burden on patients and healthcare systems, it has not yet been identified as a healthcare priority in many countries(1). In the U.S., there are approximately 26 million patients with physician-diagnosed asthma (2) . Asthma cost the U.S. economy an estimated $81.9 billion USD in 2013 alone (3) .
Conventional wisdom suggests that asthma is not a curable disease. Indeed, evidence indicates that airway hyper-responsiveness and inflammation persist in individuals whose asthma has been dormant for many years (4) . Therefore, the contemporary asthma management paradigm is based on achieving symptom control and reducing the risk of exacerbations(5). It is widely accepted that through avoidance of triggers and use of inhaled anti-inflammatory agents (namely inhaled corticosteroids [ICS]), asthma can be controlled and exacerbation risk can be significantly reduced in the majority of patients (6) .
Achieving asthma control is associated with improvement in quality of life, reduction in medical costs, and better work performance (7, 8) . Unfortunately, the reality of asthma care is highlighted by poor adherence to treatments and other disease management modalities (e.g., avoidance of triggers), resulting in a significant proportion of asthma patients experiencing suboptimal asthma control (9) .
A good understanding of the future burden of diseases can support the search for efficiency and equity in healthcare. Many studies have estimated the total burden of asthma in the U.S.(1,3,10). However, given the focus of contemporary asthma management is on achieving asthma control, the relevant figure of merit for policymaking and prioritizing future research is the burden due to suboptimal asthma control, rather than the burden of asthma itself. In a small minority of patients, achieving symptom control can be difficult or out of reach (11) . However, given the availability and efficacy of inexpensive management strategies to control asthma in the majority of patients, the excess burden between uncontrolled and controlled asthma is largely 'preventable'. Such burden can be considered as the maximum space available for contemporary asthma management strategies to reduce asthma burden at the population level. The resources required for interventions and programs aimed at improving asthma control can be juxtaposed against their estimated impact on the burden of suboptimal asthma control to evaluate whether such programs are worth implementing.
The purpose of the present study was to document the current economic and health burden as well as project the future preventable economic and health burden associated with suboptimal asthma control among the U.S. adolescent and adult population for the next 20 years. We answered the question "how much costs could be saved, and quality of life could be improved, if all adolescent and adult asthma patients in the U.S. achieve symptom control in the next 20 years?"
Methods
To enable projections, we reconciled evidence from multiple sources into a time-in-state computer model of asthma. The projection period was from 2019 to 2038 (20 years). We adopted a societal perspective in the primary analysis; thus, costs were included no matter who had incurred them. The analyses were performed for the entire U.S. population ≥14 years of age, as well as at the state level.
We defined asthma control according to the score on the Asthma Control Test (ACT) (12) . ACT was used because major sources of evidence for this study used this instrument (13) (14) (15) (16) (17) (18) (19) . This test classifies the patient's asthma status into poorly controlled (scores ≤ 15; 29.3%), not well controlled (score 16-19; 25.1%), and well controlled (score 20-25; 45.7%). As the focus was on achieving (well) controlled asthma, the outcomes of very poorly controlled and not well controlled were combined into one category (henceforth referred to as 'uncontrolled'). The supplementary material provides details of the methodology. Table 1 provides point estimates and probability distribution assigned to each model parameters.
Table1. Model input parameters *All costs are in USD 2018. †Normal(x, y): Normal distribution with mean x, and standard deviation y, lognormal(x, y), log normal distribution with mean x and standard deviation y for the log-transformed values ‡We modeled probability of three levels of control to align with calibration process and pooled "very poorly control" and "not-well control" into "uncontrolled group" in order to report outcome. 
Parameters

Data sources
We used the following six major sources of evidence to populate the model. Details of the estimated parameters and methodologies are provided in Supplementary Materials, Section 1.
1) Forecasts of population growth and aging during the projection period, nationally and for each state, were derived from the National Population Projections conducted by the Census Bureau -Population Division(20,21).We estimated the midpoint of two sets of national population projections based on the 2010 Census for bases case estimate.
2) Estimates of the prevalence of asthma, stratified by age and sex for each state, were obtained from the Global Burden of Disease (GBD) studies in 2016 (22, 23) .These studies used the systematic analysis of published literature and other sources to estimate, using a consistent methodology, the burden of several health conditions including asthma (25) .
3) Distribution of control levels in the asthma population, stratified by sex and age groups, were derived using calibration techniques from a recent study based on the U.S. National Health and Wellness Survey (NHWS) between 2011 and 2013 (13) . We estimated the sex-and age-specific distribution of control levels by solving the coefficients of a multinomial logit equation (with prevalence of asthma control levels as the outcome, and sex and age as independent variables) such that the prevalence of asthma control levels matches NHWS estimates ( Table 1) . Details of calibration techniques are provided in the Supplementary Materials (Section 1.3).
4) Healthcare resource use and quality-adjusted life years (QALY) differences across control levels were
based on dedicated literature reviews and meta-analyses. We retrieved all relevant U.S.-based studies that assessed the adjusted association between asthma control and healthcare resource utilization, overall work impairment (indirect costs), and health-related quality of life. Studies were included if they controlled for potential confounding variables. Random-effects models were used to estimate the pooled adjusted odd ratios (OR) and 95% confidence interval (95%CI) of the association between asthma control and rate of healthcare provider visits, emergency visits, hospitalizations, and medication use. In addition, we used random-effects models to estimate adjusted pooled mean difference of overall work impairment in terms of the percentage of work hours lost due to sub-optimal asthma control. Finally, we pooled mean differences in QALYs between the uncontrolled and controlled groups. Details of the search strategy and meta-analysis are provided in the Supplementary Materials (Section 1.4).
5)
We performed model calibration to convert estimates of resource use to direct costs. This method combines the distribution of asthma control levels in the population, ratio of resource use between uncontrolled and controlled asthma, and total direct costs of asthma in the U.S., to solve for the costs of uncontrolled versus controlled asthma. The first two components were obtained as described above.
For total costs of asthma in the U.S., we relied on a recent large study (n=214,000) by the Centers for Disease Control and Prevention (3). This study used population-based sampling to estimate the overall costs of asthma. We solved for the costs of uncontrolled and controlled asthma that produced the desired ratio between the two that matched the results of our meta-analysis of resource use, and summed up to the total costs of asthma. Details of this methodology are provided in the Supplementary Materials (Section 1.5).
6)
To estimate indirect costs suboptimal asthma control, we obtained the monetary value of productivity loss based on age-and sex-specific wages as reported by the Bureau of Labour Statistics(24). These estimates were combined with the results of the meta-analysis of productivity loss differences across control levels.
Analysis
All projections are made for the period of 2019 to 2038. The primary projections are made for the entire U.S. adolescent and adult asthma population. State-level projections are provided as secondary results.
In the main analysis, we estimated undiscounted total direct costs, indirect costs, and QALYs lost attributable to uncontrolled asthma. In a sensitivity analysis we calculated outcomes after applying a 3% annual discount rate, as recommended by panel on Cost-Effectiveness in Health and Medicine (26) . All costs were adjusted to 2018 U.S. dollars using historical inflation rates (27) . Uncertainty was modeled by assigning probability distributions to all input parameters (e.g., based on the reported 95%CI) and was propagated to the uncertainty in the projections using Monte Carlo simulation: within each simulation loop, we randomly drew from the distribution of all model parameters, performed model calibrations as described above, and calculated the outcomes. Uncertainty was presented in terms of 95%CIs around point estimates of projections.
Results
Systematic review and meta-analysis of resource use across control levels
We identified 10 studies that reported on the adjusted differences in direct costs, indirect costs, or
QALYs across control levels in the U.S. Forest plots for adjusted odds ratios (ORs) and mean differences are shown in Figure 1 and Figure 2 , respectively. For healthcare resource use, the pooled adjusted ORs in the uncontrolled versus the controlled group were as follows: Finally, the pooled estimate of the mean reduction in QALY values was 0.07 (95%CI 0.06 -0.09; P<0.001; 5 studies). Further details on these results are provided in the Supplementary Materials (Table E4-E7 and FigureE1).
Projection of burden of suboptimal asthma control
The size of the U.S. adolescent and adult population was projected to increase by 11%, from 266.87 million in 2019 to 298.22 million in 2038. In 2019, there will be 15.88 million adolescent/adult asthma patients in the country, which is expected to increase to 17.65 million by 2038, representing 10% growth;
62% of asthma patients will be women. During the 20-year projection window, in 175.32 million patientyears (52% of total patients-years of asthma), asthma will be sub-optimally controlled. Total undiscounted direct costs of asthma across all control levels combined over 20 years will be $1,537
billion. The total undiscounted 20-years direct costs, indirect costs, and QALYs lost associated with sub optimal controlled of asthma within age and sex group are provided in Table 2 . Direct costs: Trends of undiscounted excess direct costs due to suboptimal asthma control are shown in Figure (3-A) . In 2019, these costs will be $14.62 billion; this value will increase to $15.08 billion in 2028 and to $15.23 billion in 2038, representing a 4.1% growth during 20 years. Over this period, total direct costs associated with suboptimal asthma control will be $300.65 billion (95%CI 190.1 billion -$411.1 billion). Figure (3-B) depicts the projections for indirect costs associated with uncontrolled asthma. These costs will total $32.2 billion in 2019; this value will increase to $33. Figure (3-C) . Figure 
Indirect costs:
3.Future trends of undiscounted direct costs (A), undiscounted indirect costs (B) and QALYs loss (C) due to
sub-optimal control of asthma in the United State. Squares are point estimates and lines are confidence intervals.
Sensitivity analyses
When future values were discounted at the rate of 3 percent, projections of the burden of suboptimal asthma control changed as follows: total costs decreased to $210.4 billion (95%CI $133 billion -$287.7 billion), total indirect costs decreased to $463.9 billion (95%CI $331.7 billion -$596.1 billion), and total
QALYs lost decreased to 10.82 million (95%CI 8.94 -12.70 million).
State-level analysis
Results of state-level analyses are provided in Figure 4 and in Supplementary Materials (Table E8 ). We divided the total burden over the projected population size for each state to estimate the average 
Discussion
We predicted the overall burden of uncontrolled asthma over the 2019 -2038 period in the U.S. adolescent and adult population, in total and across states, if no paradigm shift occurs in the contemporary asthma management. Of the 175.3 million patient-years with asthma in the next 20 years, 52% will be associated with suboptimal asthma control. Total undiscounted direct costs of asthma, across all levels of control, will be $1,537 billion during this period; however, if all patients achieve asthma control during the next 20 years, $300.6 billion in direct costs can be saved. Our results therefore indicate that around 20% of direct costs of asthma can potentially be prevented by achieving asthma control in the population. When indirect costs are added, the potentially preventable burden of sub-optimally controlled asthma will be $963.5 billion. In addition, there will be $15.46 million QALYs lost due to suboptimal asthma control over this period.
Indeed, strategies and interventions towards better asthma control are likely to be associated with costs, and are unlikely to result in complete asthma control in all patients. As such, these values can be seen as population-based estimates of the maximum potential return on investment from strategies that are aimed at improving asthma control. Previous research from the U.S. has repeatedly showed that the prevalence of uncontrolled asthma is remarkably higher than the proportion of patients that fail to achieve asthma control in clinical trials (13) (14) (15) . Multiple factors are considered as potential culprits for such discrepancy. Such factors include failure to avoid asthma triggers, unacceptably low adherence to controlled medication in asthma patients (9) , inefficient uptake of inhaled medications due to poor inhalation techniques(28), over-reliance on reliever versus controller use by both care providers and patients(29), to name a few.
To the best of our knowledge, ours is the first study that provides projections of asthma burden due to suboptimal asthma control. A 2005 study calculated burden of uncontrolled asthma in a managed care setting in U.S., and reported an incremental two-year mean total costs of $7,760 (in 2015 $, equal to incremental one-year costs of $4,873 in 2018 $) between uncontrolled and controlled asthma (30) . This estimation is higher than our baseline estimate ($4,699), but nonetheless within the 95%CI of our results.
We have previously conducted a similar analysis in the Canadian context using a similar methodology (31 (33) .
The strengths of our study include the use of diverse sources of evidence (projection of population growth and aging, prevalence of asthma, distribution of asthma control levels, estimates of resource use and direct and indirect costs and loss of quality of life across control levels). The choice of the analytical framework allowed us to translate such evidence and associated uncertainties into estimates of burden.
We conducted multiple systematic reviews and meta-analyses to ensure our estimates of resource use differences across control levels reflect the available evidence. The use of model calibration techniques allowed us to estimate parameters that were not obtainable directly but were estimated such that they remained compatible with evidence studies. For example, we solved for cost values associated with control levels that reflected the differences in healthcare resource use of various types between uncontrolled and controlled asthma, in the meantime adding up to the reported overall costs of asthma from a recent large and representative study (3) . The limitations of this study should also be mentioned.
Our study assumes the overall prevalence of asthma across age and sex groups will stay the same during the projection period. While such a 'default' assumption makes sense for estimating baseline projections for future burden of a disease, it is likely that the contribution of many risk factors (e.g., environmental and occupational pollutions) will change over this time, and the reported ranges (i.e., 95%
CIs) in our projections do not reflect this source of uncertainty. Similarly to risk factors, novel therapies will arrive and guidelines and best practice recommendations will change, adding further uncertainty to predictions that are not captured in our results. In addition, the quality of the projections cannot be higher than the quality of the underlying evidence. For example, the observed difference between the burden of uncontrolled and controlled asthma is likely to be confounded by many factors namely the severity of underlying disease. As such, the estimate of the reduction in burden once asthma control is achieved relies on the extent original studies successfully controlled confounding factors. Further, different studies have used different definition of asthma control (e.g., based on cut-offs on the ACT test or symptom control as defined by Global Initiative for Asthma). While we attempted to use a consistent definition of control, the availability of evidence forced us to relax this assumption at times; for example, in estimating the association between outcomes and controlled levels, we considered other definitions of asthma control ,such as Global Initiative for Asthma(GINA) and National Asthma Education and Prevention Program (NAEPP) as equivalent of ACT in three studies (8, 34, 35) .
Our findings highlight the sizeable potential for cost saving and improvement in quality of life associated with better asthma control. The conversations about the burden of asthma should focus on the aspects of the burden that can realistically be prevented, rather than just focusing on the overall burden of asthma. As well, research into improving adherence to existing medications should be put on an equal footing with investments in novel asthma therapies. Many of the effective asthma therapies are now off-patent, and research and development in the private sector are understandably shifted towards developing novel therapies. However, healthcare management organizations, patient groups, governments, and society at large, will benefit from investing in areas with proven capacities for improving patient outcomes and reducing costs.
